Abivax SA (ABVX PA) stock market data APIs
€7.2247
-0.08(-1.1%)
as of July 14, 2025
Try our APIs with
free plan!
Abivax SA Financial Data Overview
Price chart is built with
Anychart
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Prev. Close
7.2247
Open
7.1446
High
7.5162
Low
6.9417
52 wk Range
4.51-12.68
Market Cap
463 M
Shares Outstanding
63 472 K
Revenue
10 588 K
EPS
-0.83
Beta
1.509
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Abivax SA data using free add-ons & libraries
Get Abivax SA Fundamental Data
Abivax SA Fundamental data includes:
- Net Revenue: 10 588 K
- EBITDA: -174 394 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-02
- EPS/Forecast: -0.6561
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Abivax SA News
New
Abivax Announces the Appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors
PARIS, FRANCE / ACCESSWIRE / July 11, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune...
Abivax receives "Capital Market Transaction of the Year Award" at the European Mediscience Awards 2023
The award recognizes a significant capital market transaction in the biotech sector Abivax received the award for its oversubscribed EUR 130M cross-over financing at market price with top-tier US and ...
Abivax Stock Included in MSCI Indexes
As of June 1st, the Abivax stock is represented in the MSCI Indexes The MSCI Indexes reflect the evolution of the world's equity markets to support investors building effective portfolios based on ris...
Abivax Releases the Results of its June 5, 2023 Ordinary and Extraordinary General Meeting
Shareholders approved all proposed resolutions PARIS, FRANCE / ACCESSWIRE / June 8, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on d...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
